论文部分内容阅读
目的:探讨原发性乳腺癌组织中tau蛋白的表达与乳腺癌紫杉类药物新辅助化疗敏感性的关系。方法:应用免疫组化法对113例原发性乳腺癌患者术前穿刺样本进行tau蛋白表达水平的检测,分析其与紫杉类药物化疗敏感性的关系。结果:乳腺癌组织中tau蛋白表达的阳性率为24.78%(28/113);紫杉类药物新辅助化疗后,达到病理完全缓解(pCR)的患者40例,存在残留癌的患者73例。pCR组tau蛋白阳性率为12.50%(5/40),残留癌组tau蛋白阳性率为31.51%(23/73),两者之间差异有统计学意义,χ2=5.008,P=0.025。结论:tau蛋白表达水平与乳腺癌紫杉类药物化疗敏感性呈负相关,检测tau蛋白表达状态对预测乳腺癌紫杉类药物新辅助化疗的敏感性可能具有一定的指导意义。
Objective: To investigate the relationship between the expression of tau protein and the sensitivity of neoadjuvant chemotherapy for breast cancer taxane in patients with primary breast cancer. Methods: The expression of tau protein in 113 cases of primary breast cancer before operation was detected by immunohistochemistry. The relationship between them and the chemosensitivity of taxanes was analyzed. Results: The positive rate of tau protein expression in breast cancer was 24.78% (28/113). After neoadjuvant chemotherapy of taxanes, 40 patients achieved pathologic complete remission (pCR) and 73 patients had residual cancer. The positive rate of tau protein in pCR group was 12.50% (5/40), and the positive rate of tau protein in residual cancer group was 31.51% (23/73). There was a significant difference between the two groups (χ2 = 5.008, P = 0.025). Conclusion: The expression level of tau protein is negatively correlated with chemosensitivity of taxane in breast cancer. To detect the expression of tau protein may be helpful to predict the sensitivity of neoadjuvant chemotherapy of breast cancer taxane.